Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mirogabalin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 known ✓ | P54289 | 4/20 | 0.52 |
| ▸ | CACNB3 | P54284 | 4/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mirogabalin SCHEMBL1888044 | 1.00 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1CAKR1B1CYP3A4 | |
| Mirogabalin SCHEMBL1814664 | 1.00 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1CAKR1B1CYP3A4 | |
| Mirogabalin SCHEMBL1814663 | 1.00 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1CAKR1B1CYP3A4 | |
| Mirogabalin SCHEMBL18051452 | 1.00 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1CAKR1B1CYP3A4 | |
| Mirogabalin SCHEMBL18051438 | 1.00 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1CAKR1B1CYP3A4 | |
| Mirogabalin SCHEMBL1816421 | 1.00 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1CAKR1B1CYP3A4 | |
| Mirogabalin SCHEMBL1888046 | 1.00 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1CAKR1B1CYP3A4 | |
| Mirogabalin SCHEMBL1816422 | 1.00 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1CAKR1B1CYP3A4 | |
| SCHEMBL1880871 | 0.89 | CACNB3 (0.42) | CACNB3CACNA2D1CACNA1C | |
| SCHEMBL1880872 | 0.89 | CACNB3 (0.42) | CACNB3CACNA2D1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2719677-B1 | METHOD FOR PRODUCING BICYCLIC COMPOUND VIA CLAISEN REARRANGEMENT | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2719677-B1 | METHOD FOR PRODUCING BICYCLIC COMPOUND VIA CLAISEN REARRANGEMENT | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2412700-B1 | METHOD FOR PRODUCING BICYCLIC GAMMA-AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-09 | — | — | EP | disclosed |
| EP-2412700-B1 | METHOD FOR PRODUCING BICYCLIC GAMMA-AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-09 | — | — | EP | disclosed |
| US-9206104-B2 | Methods for producing bicyclic compounds via iminium salt | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206104-B2 | Methods for producing bicyclic compounds via iminium salt | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206104-B2 | Methods for producing bicyclic compounds via iminium salt | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9162971-B2 | Methods for producing bicyclic compounds via claisen rearrangements | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-20 | — | — | US | disclosed |
| US-9162971-B2 | Methods for producing bicyclic compounds via claisen rearrangements | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-20 | — | — | US | disclosed |
| US-9162971-B2 | Methods for producing bicyclic compounds via claisen rearrangements | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-20 | — | — | US | disclosed |
| EP-2719676-A1 | METHOD FOR PRODUCING BICYCLIC COMPOUND VIA IMINIUM SALT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8324425-B2 | Method for producing bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8324425-B2 | Method for producing bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8324425-B2 | Method for producing bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20120071685-A1 | METHOD FOR PRODUCING BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071685-A1 | METHOD FOR PRODUCING BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071685-A1 | METHOD FOR PRODUCING BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2412700-A1 | METHOD FOR PRODUCING BICYCLIC GAMMA-AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-2412700-A1 | METHOD FOR PRODUCING BICYCLIC GAMMA-AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110361-A1 | METHOD FOR PRODUCING BICYCLIC Γ-AMINO ACID DERIVATIVE | 第一三共株式会社 (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071685-A1 | METHOD FOR PRODUCING BICYCLIC gamma-AMINO ACID DERIVATIVE | ADRA2A, GABRB2, ADRB2 | CACNA2D1 179/4885CACNB3 238/4885CACNA1C 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.